This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
Marco Antonio Stephano
Advertisement
Marco Antonio Stephano is professor at the University of Sao Paulo, Sao Paulo, Brazil.
Articles by Marco Antonio Stephano
Advertisement
Latest Updated Articles
Brazilian Regulation of Biosimilar Products: What Is Important to KnowPublished: September 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
